Glioblastoma is the most common malignant primary intracranial tumor and, despite multi-modal treatment, the prognosis remains poor. Additional tools to improve early detection or evaluate treatment response are highly desirable. We evaluated serial ADC measurements in the T2-hyperintense, but otherwise normal-appearing white matter at 1.5 T in thirty-five subjects diagnosed with glioblastoma and treated by surgical resection, radiotherapy, temozolomide and tumor-treating fields. We found that serially increasing ADC in the T2-hyperintense, but otherwise normal-appearing white matter in glioblastoma patients is prognostically favorable, with significantly greater overall survival and progression-free survival in patients with increasing ADC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords